Cargando…
PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil
Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melan...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047789/ https://www.ncbi.nlm.nih.gov/pubmed/36980349 http://dx.doi.org/10.3390/diagnostics13061041 |
_version_ | 1785014015362072576 |
---|---|
author | Sorroche, Bruna Pereira Teixeira, Renan de Jesus Pereira, Caio Augusto Dantas Santana, Iara Viana Vidigal Vujanovic, Lazar Vazquez, Vinicius de Lima Arantes, Lidia Maria Rebolho Batista |
author_facet | Sorroche, Bruna Pereira Teixeira, Renan de Jesus Pereira, Caio Augusto Dantas Santana, Iara Viana Vidigal Vujanovic, Lazar Vazquez, Vinicius de Lima Arantes, Lidia Maria Rebolho Batista |
author_sort | Sorroche, Bruna Pereira |
collection | PubMed |
description | Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melanoma. A retrospective analysis was performed on 210 patients treated with PD-1 or CTLA-4 inhibitors at Barretos Cancer Hospital, Brazil. PD-L1 expression was assessed by immunohistochemistry using formalin-fixed paraffin-embedded tumor tissues collected prior to ICB therapy. Patients were divided into responders (complete and partial response and stable disease for more than 6 months) and non-responders (stable disease for less than 6 months and progressive disease). Among them, about 82% underwent anti-PD-1 immunotherapy, and 60.5% progressed after the ICB treatment. Patients that received ICB as first-line therapy showed higher response rates than previously treated patients. Higher response rates were further associated with superficial spreading melanomas and positive PD-L1 expression (>1%). Likewise, PD-L1 positive expression and BRAF V600 mutations were associated with a higher overall survival after ICB therapy. Since ICBs are expensive therapies, evaluation of PD-L1 tumor expression in melanoma patients should be routinely assessed to select patients that are most likely to respond. |
format | Online Article Text |
id | pubmed-10047789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-100477892023-03-29 PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil Sorroche, Bruna Pereira Teixeira, Renan de Jesus Pereira, Caio Augusto Dantas Santana, Iara Viana Vidigal Vujanovic, Lazar Vazquez, Vinicius de Lima Arantes, Lidia Maria Rebolho Batista Diagnostics (Basel) Article Immune checkpoint blockade (ICB) agents are prominent immunotherapies for the treatment of advanced melanoma. However, they fail to promote any durable clinical benefit in a large cohort of patients. This study assessed clinical and molecular predictors of ICB response and survival in advanced melanoma. A retrospective analysis was performed on 210 patients treated with PD-1 or CTLA-4 inhibitors at Barretos Cancer Hospital, Brazil. PD-L1 expression was assessed by immunohistochemistry using formalin-fixed paraffin-embedded tumor tissues collected prior to ICB therapy. Patients were divided into responders (complete and partial response and stable disease for more than 6 months) and non-responders (stable disease for less than 6 months and progressive disease). Among them, about 82% underwent anti-PD-1 immunotherapy, and 60.5% progressed after the ICB treatment. Patients that received ICB as first-line therapy showed higher response rates than previously treated patients. Higher response rates were further associated with superficial spreading melanomas and positive PD-L1 expression (>1%). Likewise, PD-L1 positive expression and BRAF V600 mutations were associated with a higher overall survival after ICB therapy. Since ICBs are expensive therapies, evaluation of PD-L1 tumor expression in melanoma patients should be routinely assessed to select patients that are most likely to respond. MDPI 2023-03-09 /pmc/articles/PMC10047789/ /pubmed/36980349 http://dx.doi.org/10.3390/diagnostics13061041 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Sorroche, Bruna Pereira Teixeira, Renan de Jesus Pereira, Caio Augusto Dantas Santana, Iara Viana Vidigal Vujanovic, Lazar Vazquez, Vinicius de Lima Arantes, Lidia Maria Rebolho Batista PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil |
title | PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil |
title_full | PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil |
title_fullStr | PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil |
title_full_unstemmed | PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil |
title_short | PD-L1 Tumor Expression as a Predictive Biomarker of Immune Checkpoint Inhibitors’ Response and Survival in Advanced Melanoma Patients in Brazil |
title_sort | pd-l1 tumor expression as a predictive biomarker of immune checkpoint inhibitors’ response and survival in advanced melanoma patients in brazil |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10047789/ https://www.ncbi.nlm.nih.gov/pubmed/36980349 http://dx.doi.org/10.3390/diagnostics13061041 |
work_keys_str_mv | AT sorrochebrunapereira pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil AT teixeirarenandejesus pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil AT pereiracaioaugustodantas pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil AT santanaiaravianavidigal pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil AT vujanoviclazar pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil AT vazquezviniciusdelima pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil AT aranteslidiamariarebolhobatista pdl1tumorexpressionasapredictivebiomarkerofimmunecheckpointinhibitorsresponseandsurvivalinadvancedmelanomapatientsinbrazil |